A5070212
Icariin , 96% , 489-32-7
Synonym(s):
4′-O-methyl-8-γ,γ-dimethylallylkaempferol-3-rhamnoside-7-glucoside
CAS NO.：489-32-7
Empirical Formula: C33H40O15
Molecular Weight: 676.66
MDL number: MFCD00210516
EINECS: 610-440-0
| Pack Size | Price | Stock | Quantity |
| 250MG | RMB74.40 | In Stock |
|
| 1G | RMB199.20 | In Stock |
|
| 200mg | RMB440.00 | In Stock |
|
| 5G | RMB740.00 | In Stock |
|
| 25G | RMB2800.80 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 223-225 ºC |
| alpha | D15 -87.09° (in pyridine) |
| Boiling point: | 948.5±65.0 °C(Predicted) |
| Density | 1.55 |
| RTECS | DJ2980500 |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble50mg/mL, clear, colorless to dark yellow |
| form | Powder |
| pka | 5.90±0.40(Predicted) |
| color | light yellow to yellow |
| λmax | 350nm(MeOH)(lit.) |
| Merck | 14,3617 |
| Stability: | Light Sensitive |
| InChIKey | TZJALUIVHRYQQB-XLRXWWTNSA-N |
| LogP | 1.736 (est) |
Description and Uses
Icariin has been used:
- in the preparation of topical treatment to determine its effects on the improvement of cutaneous wound healing in rats
- to test its analgesic effects on lower back pain (LBP) in rats
- as a potential treatment in osteoporosis condition in rats
- to study its effects on palmitate (PA)-induced insulin resistance in skeletal muscle C2C12 myotubes
- as a neuroprotective agent to study its effects on amyloid-β (Aβ)-induced neuronal insulin resistance in human neuroblastoma SK-N-MC cells
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319 |
| Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
| Safety Statements | 24/25 |
| WGK Germany | 3 |
| HS Code | 29389090 |
